Nemaura touts data for Memspatch insulin micro-needle device

Nemaura Pharma‘s Memspatch insulin micro-needle device compared well against a pen injector in an 18-patient clinical trials, according to the company.

The group of Type I diabetic patients were given insulin using either the Memspatch device or a traditional pen injector. Researchers evaluated the patient’s pain levels using a number pain rating score from 0 to 10. Patients were also asked to record their experiences with the devices and to reflect on the pain immediately following administration.

Get the full story at our sister site, Drug Delivery Business News.

The post Nemaura touts data for Memspatch insulin micro-needle device appeared first on MassDevice.

from MassDevice http://ift.tt/2pPE54t